Memphasys Ltd
ASX:MEM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.003
0.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Memphasys Ltd
Memphasys Ltd. is a life sciences company. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The company develops medical devices, diagnostics and media with application to assists reproduction technologies in humans and animals. The Company’s lead product is Felix device. The Felix is an automated device for separating quality sperm from a semen sample for the use in human in vitro fertilization (IVF) procedures. The firm's membrane technology utilizes its separation technology along with its multiple devices and hydrogel membranes to fractionate biological molecules. The technology relies on the applied electric field and charged biological molecules. The sample and harvest chamber are formed by placing the separation membrane in between two restriction membranes with restricted pores.
Memphasys Ltd. is a life sciences company. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The company develops medical devices, diagnostics and media with application to assists reproduction technologies in humans and animals. The Company’s lead product is Felix device. The Felix is an automated device for separating quality sperm from a semen sample for the use in human in vitro fertilization (IVF) procedures. The firm's membrane technology utilizes its separation technology along with its multiple devices and hydrogel membranes to fractionate biological molecules. The technology relies on the applied electric field and charged biological molecules. The sample and harvest chamber are formed by placing the separation membrane in between two restriction membranes with restricted pores.